<DOC>
	<DOC>NCT00541697</DOC>
	<brief_summary>A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.</brief_summary>
	<brief_title>Eze/Simva Switch Study in Diabetics (0653A-807)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Currently being treated with Atorvastatin 10 mg for at least 6 weeks Have Type 2 Diabetes Weight must be stable for more than 6 weeks before entering the study Consume more than 14 alcoholic drinks per week. Pregnant or lactating Have taken another investigation drug within 3 months of starting this study History of congestive heart failure, heart attack, coronary artery bypass surgery Uncontrolled high blood pressure HIV positive History of cancer in the last 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>